Section Summary

Selection of a payload is based on mechanism of action – DNA damage, Topoisomerase inhibition, Microtubule inhibition etc. Apart from the mechanism the physico-chemical properties – hydrophilicity, linker binding sites, stability under various conditions – contribute as much towards its success. DAR, apart from antibody affinity discussed in Section 6 impacts peripheral binding or deep tumor penetration.

A well-designed clinical trial integrates and exploits complete understanding of the properties of the payload, and that contributes to demonstrating statistically significant efficacy.

In contemporary ADC development—and particularly in CEACAM5-directed programs—the competition driver has shifted downstream toward payload architecture. All three leaders have given signals acknowledging and endorsing this view. EMD’s patents indicate it is developing payload as platform; Pfizer and BMS have made significant acquisitions for proprietary technologies in the area.

Payload is influencing targeting, application to which class of tumors, and is expected to generate premium positioning This shift is especially visible in CEACAM5.

Among the 187 CEACAM5 clinical studies evaluated in this report, only a single program was terminated primarily due to adverse events subsequently attributed to payload-related effects. Although the sample should not be over interpreted, it provides an important signal: development teams appear increasingly disciplined in payload selection and increasingly sophisticated in matching payload biology to clinical context.

At the time of release of this report, the payload story is bifurcating — one branch is optimizing cytotoxic potency and bystander killing (DXd/exatecan dominating), while the other branch is pivoting to immunostimulatory payloads to address non-proliferating and immune-cold tumors where pure cytotoxins consistently underperform. The IBI3020 dual-payload strategy (if it’s CEACAM5 × TOP1i + RNA Pol II inhibitor) straddles both branches — which is exactly why it deserves close attention.

Four observations emerge.

First, topoisomerase-I inhibitor (TOP1i) payloads currently define the clinical reference standard in CEACAM5.

Second, linker and conjugation advances are progressively expanding the usable payload universe by improving retention, lowering systemic exposure, and widening therapeutic windows.

Third, and strategically most important—the next generation of CEACAM5 differentiation may emerge from orthogonal payload classes including immunostimulatory conjugates, targeted protein degraders, dual-payload systems, and radiotherapeutic approaches creating best in class molecules.

Fourth, Clinical development strategies are playing an interesting role in elucidating the properties of Payloads, and will play a critical role in how the market gets segmented in the coming few to several years.

This Section evaluates the current payload landscape, adjacent patent ownership signals, clinical implications, white spaces, and strategic options for future CEACAM5 entrants, expanding the framework for due diligence to obtain rational valuations.

Part of the three-component architecture analysed in Section 5. Antibody and linker analyses are in Section 6 and Section 8.